PMID- 8624791
OWN - NLM
STAT- MEDLINE
DCOM- 19960625
LR  - 20151119
IS  - 1125-0135 (Print)
IS  - 1125-0135 (Linking)
VI  - 39
IP  - 4
DP  - 1995 Dec
TI  - Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 
      21.1) immunoradiometric assay in non small cell lung cancer evaluation.
PG  - 285-9
AB  - The aim of our work was the evaluation of the immunoradiometric assay (IRMA) of 
      two cytokeratinic markers, TPS and CYFRA 21.1, in clinical setting on non small 
      cell lung cancer (NSCLC). Serum samples were obtained from 148 untreated NSCLC 
      patients, 60 patients with non malignant lung diseases and 100 healthy subjects: 
      TPS and CYFRA 21.1 serum levels were assayed by IRMA methods. Diagnostic 
      performance of the markers was evaluated and the TPS and CYFRA 21.1 distribution 
      analysed according to some different clinical and biological variables as 
      histological subtypes, stage and survival time by using the Mann-Whitney 
      "U"-test. Sensitivity, specificity and accuracy were 0.54 (80/148), 0.47 (28/60), 
      0.52 (108/208) and 0.73 (108/148), 0.74 (44/60), and 0.73 (152/208) for TPS and 
      CYFRA 21.1 respectively. CYFRA 21.1 demonstrate a higher sensitivity than TPS in 
      all stages of the disease and in the spinocellular and adenocarcinoma 
      histological subtypes while TPS sensibility is higher in large cell carcinoma. 
      The CYFRA 21.1 specificity is better than TPS probably by reason of its 
      preferential distribution in respiratory epithelium. Both markers serum levels 
      differ significantly between Stage I-II and IV and between Stage I-II-IIIa and 
      IIIb-IV but neither TPS nor CYFRA 21.1 can discriminate Stage IIIa from IIIb. No 
      significant differences were found in the serum expression of the markers by the 
      different histological subtypes. A value of both markers less than the selected 
      cut-off is related to a longer survival of the patients apart from therapy (p < 
      0.05). Our conclusion supports similar behaviour of these markers in NSCLC and 
      indicates CYFRA 21.1 as the more needed biochemical index to evaluate NSCLC 
      patients.
FAU - Giovanella, L
AU  - Giovanella L
AD  - Nuclear Medicine Department, University Regional Hospital of Varese, Italy.
FAU - Ceriani, L
AU  - Ceriani L
FAU - Bandera, M
AU  - Bandera M
FAU - Rimoldi, R
AU  - Rimoldi R
FAU - Beghe, B
AU  - Beghe B
FAU - Roncari, G
AU  - Roncari G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Q J Nucl Med
JT  - The quarterly journal of nuclear medicine : official publication of the Italian 
      Association of Nuclear Medicine (AIMN) [and] the International Association of 
      Radiopharmacology (IAR)
JID - 9512274
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (tissue polypeptide specific antigen)
RN  - 68238-35-7 (Keratins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Non-Small-Cell Lung/*diagnosis
MH  - Female
MH  - Humans
MH  - Immunoradiometric Assay
MH  - Keratins/*analysis
MH  - Lung Neoplasms/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*analysis
MH  - Peptides/*analysis
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
PST - ppublish
SO  - Q J Nucl Med. 1995 Dec;39(4):285-9.